Le Lézard
Classified in: Health
Subject: PLW

Sytheon Granted 2 New US Patents on Isosorbide Diesters for Treating Atopic Dermatitis, Seeking Exclusive Partner to Bring to Market


PARSIPPANY, N.J., Dec. 13, 2023 /PRNewswire/ -- Sytheon is thrilled to announce that its new turnkey product for treating Atopic Dermatitis (eczema) has further patent protection ? and is actively seeking an exclusive partner to bring it to the OTC dermatological market.

Sytheon is thrilled to announce that its new turnkey product for treating eczema has further patent protection.

There is currently an unmet need for a sustainable, safe, and cost-effective product for those with mild to moderate Atopic Dermatitis (AD). Sytheon has a turnkey product, ActSES®, with solid science, patent protection, and clinical validation by UC-Davis, CA dermatologists ? and a new clinical study on children underway.

Market Opportunity for Atopic Dermatitis (AD)
Topical therapies are a mainstay treatment for AD, particularly for children or those with mild-to-moderate disease who may not qualify for systemic medications. The complexity of chronic AD is increased by the interplay of skin barrier dysfunction and immune dysregulation, resulting in the perpetuation of AD signs and symptoms.

ActSES®, a unique synergistic combination product of Isosorbide di-(linoleate/oleate) (Hydra Synol® IDL) + Isosorbide di-caprylate (Hydra Synol® DOI), has been developed by Sytheon to serve this unmet need. The effects of topically applied ActSES® are not limited to barrier repair but synergistically inhibit inflammatory cascades that amplify pruritus and cutaneous eruption.

For ActSES®, Sytheon has obtained two new US patents 11,753,414 (method) & 11,753,415 (composition), entitled "Composition and Methods for Treating Atopic Dermatitis." Sytheon has two earlier US Patents (10,597,402 & 11,312,725), which disclose "compositions and methods for restoring epidermal integrity and function and treating dermatol­ogical diseases."

Sytheon is actively looking for an exclusive partnership with the right organization to bring this turnkey product to the OTC dermatological market. To inquire, please send us a message here.
This news piece is also featured on SpecialChem and HAPPI.

About Sytheon
Sytheon is an innovative research-focused company committed to developing high-performance active ingredients for the personal care industry. Inspired by nature, all of Sytheon's ingredients have been scientifically and clinically validated to improve the health and beauty of the skin.
Visit our website: www.sytheonltd.com

SOURCE Sytheon Ltd.


These press releases may also interest you

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...



News published on and distributed by: